Metropolis Healthcare working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

52.49×	52.49×	58.78×	62.66×	68.96×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
35.29×	35.29×	37.60×	37.50×	40.91×
143.56×	143.56×	153.03×	145.60×	135.59×
−55.78×	−55.78×	−56.65×	−45.44×	−25.72×
12.71×	12.23×	25.80×	17.26×	30.41×
0.82×	0.82×	0.78×	0.79×	0.76×
1.83×	1.83×	1.81×	2.06×	1.72×
0.87×	0.87×	0.87×	0.93×	0.86×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

METROPOLIS₹553.85

Metropolis Healthcare Ltd.

· Pharma & Health

₹ CrorePeersLALPATHLAB VIJAYA THYROCARE MARKSANS PARKHOSPS JLHL RUBICON HCGMcap ₹11,483 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	68.96	62.66	58.78	52.49	52.49
Receivable Days (DSO)	40.91	37.50	37.60	35.29	35.29
Payable Days (DPO)	135.59	145.60	153.03	143.56	143.56
Cash Conversion Cycle (days)	-25.72	-45.44	-56.65	-55.78	-55.78
Working Capital Turnover	30.41	17.26	25.80	12.23	12.71
Asset Turnover	0.76	0.79	0.78	0.82	0.82
Cash Conversion (CFO/Net Income)	1.72	2.06	1.81	1.83	1.83
CFO/EBITDA	0.86	0.93	0.87	0.87	0.87

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.